Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 3/20 | 0.41 |
| ▸ | CDK9 | P50750 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | JAK1 | P23458 | 3/20 | 0.41 |
| ▸ | EED | O75530 | 1/20 | 0.39 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.39 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.39 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.39 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 3/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | ABL2 | P42684 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28618092 | 0.89 | JAK2 (0.47) | JAK2JAK1PARP1 | |
| SCHEMBL28607992 | 0.84 | PARP1 (0.44) | JAK2JAK1PARP1 | |
| SCHEMBL28607007 | 0.83 | PARP1 (0.48) | JAK2JAK1PARP1 | |
| SCHEMBL27908945 | 0.83 | EGFR (0.38) | CCNT1CDK9JAK2JAK1USP30 | |
| SCHEMBL27908947 | 0.82 | GPR119 (0.41) | CCNT1CDK9JAK2JAK1USP30 | |
| SCHEMBL359420 | 0.79 | PARP1 (0.45) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL1422383 | 0.75 | PARP1 (0.46) | JAK2JAK1USP30PARP1 | |
| SCHEMBL31749704 | 0.75 | FPR2 (0.44) | JAK2JAK1EEDRBBP4SUZ12 | |
| SCHEMBL25197622 | 0.74 | DPP4 (0.44) | USP30MAPT | |
| SCHEMBL20606506 | 0.74 | IRAK4 (0.46) | EEDRBBP4SUZ12EZH2AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007733-B1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | MSD ITALIA SRL (IT) | 2016-05-25 | — | — | EP | disclosed |
| US-20110201657-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-08-18 | — | — | US | disclosed |
| US-20090275619-A1 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275619-A1 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | CCNT1 266/4885CDK9 139/4885JAK2 1768/4885 |
| US-20110201657-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | PARP1, PARP3, PARP2 | CCNT1 266/4885CDK9 139/4885JAK2 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.